China Securities Intelligent Finance: Betta Pharmaceuticals(300558) announced on the evening of November 2 that, in order to further expand its new drug innovation technology platform and enrich its product pipeline layout, the company has reached a strategic cooperation with Jiangsu Shengsi Biopharmaceutical Co., Ltd. and Hangzhou Shengsi Biopharmaceutical Co., Ltd. (the latter two are collectively referred to as "Shengsi Biopharmaceutical"). Betta Pharmaceuticals will support Shengsi Biopharmaceutical in R&D, clinical trials, production, registration and sales promotion, and promote the R&D and commercialization of related products.

On the same day, the company's wholly-owned subsidiary, Zhejiang Beta Pharmaceutical Sales Co., Ltd., signed a "Commercial Cooperation Agreement" with Hangzhou Shengsi Biotechnology, and was granted the exclusive distribution rights for FRSW117 products in the Greater China region.

According to the announcement, the target product FRSW117 is a therapeutic biological product.Class 1, intended for routine prophylaxis, on-demand treatment, and perioperative bleeding management in patients with hemophilia A, with prophylactic treatment administration frequency up to once a week. This product is a long-acting recombinant factor VIII, and has completed Phase III clinical trials. No similar domestically produced products have yet been launched on the market.

Shengsi Bio focuses on long-acting recombinant proteinsinnovative drugsIn terms of drug research and development, a full-range product pipeline for hemophilia has been established.

The announcement stated that the company and its wholly-owned subsidiaries intend to enter the recombinant coagulation factor market through this cooperation, further expanding the company's product portfolio, which aligns with its development strategy. However, given that the target product has not yet been approved for market launch, there are uncertainties regarding future research and development, production, and sales. Investors are advised to be aware of the investment risks.

Betta Pharmaceuticals' main business is the research, development, production, and sales of innovative drugs . In the first three quarters, the company achieved a net profit attributable to the parent company of 317 million yuan, a year-on-year decrease of 23.86%.

Source: https://finance.eastmoney.com/a/202511023552733992.html